Search research articles
Contact Us
Filters
Showing results (261-270 of 397) with videos related to
Page
of 40
Sort By:
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2021
Author response to Cunha <i>et al</i>
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
JCO Precision Oncology
|
July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
Mohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers
Vivek Subbiah, Ravi Murthy, David S Hong, et al.
Oncotargets and Therapy
|
May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Journal for Immunotherapy of Cancer
|
February 16, 2021
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
Nina M Muñoz, Malea Williams, Katherine Dixon, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
David S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Oncotarget
|
October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
Rabih Said, Yang Ye, Gerald Steven Falchook, et al.
Page
of 40
Search research articles
Search
Showing results (261-270 of 397) with videos related to
Sort By:
Page
of 40
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2021
Author response to Cunha <i>et al</i>
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
JCO Precision Oncology
|
July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
Mohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers
Vivek Subbiah, Ravi Murthy, David S Hong, et al.
Oncotargets and Therapy
|
May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Journal for Immunotherapy of Cancer
|
February 16, 2021
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
Nina M Muñoz, Malea Williams, Katherine Dixon, et al.
Journal for Immunotherapy of Cancer
|
May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
David S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Oncotarget
|
October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
Rabih Said, Yang Ye, Gerald Steven Falchook, et al.
Page
of 40